High dose IVIG (+/- Rituximab) desensitization alters sCD30 and BAFF levels in highly HLA sensitized patients

被引：0
|
作者：
Lai, Chih-Hung [1 ]
Vo, Ashley [1 ]
Toyoda, Mieko [1 ]
Jordan, Stanley [1 ]
Reinsmoen, Nancy L. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2008年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
下载
收藏
页码：473 / 473
页数：1
相关论文
共 50 条
  • [21] Comparison of Induction Therapy with Campath 1H vs Zenapax® in Highly-HLA Sensitized Patients (HS) Transplanted after Desensitization with IVIG plus Rituximab
    Vo, Ashley A.
    Lee, Roland
    Lin, Jennifer
    Kahwaji, Joseph
    Toyoda, Mieko
    Ge, Shili
    Peng, Alice
    Villicana, Rafael
    Jordan, Stanley C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 317 - 317
  • [22] Long term graft and patient outcomes in highly-HLA sensitized (HS) patients desensitized with high dose (HD) IVIG
    Peng, Alice
    Vo, Ashley
    Villicana, Rafael
    Lee, Richard
    Dafoe, Donald
    Reinsmoen, Nancy
    Skinner, Edwina
    Jordan, Stanley
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 352 - 352
  • [23] Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
    Vo, Ashley A.
    Peng, Alice
    Toyoda, Mieko
    Kahwaji, Joseph
    Cao, Kai
    Lai, Chih-Hung
    Reinsmoen, Nancy L.
    Villicana, Rafael
    Jordan, Stanley C.
    TRANSPLANTATION, 2010, 89 (09) : 1095 - 1102
  • [24] Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG plus Rituximab Desensitization (DES).
    Vo, A.
    Aubert, O.
    Edmund, H.
    Peng, A.
    Najjar, R.
    Supreet, S.
    Choi, J.
    Lim, K.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 516 - 516
  • [25] Comparison of two desensitization strategies using IVIG and Rituximab to improve transplantation rates in highly-HLA sensitized patients (HS) awaiting living (LD) and deceased donor (DD) transplants
    Vo, Ashley A.
    Chang, Robert
    Toyoda, Mieko
    Reinsmoen, Nancy
    Lukovsky, Marina
    Peng, Alice
    Villicana, Rafael
    Jordan, Stanley C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 353 - 353
  • [26] IVIG plus Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation
    Najjar, R.
    Huang, E.
    Vo, A.
    Cho, J.
    Louis, S.
    Hang, A.
    Peng, A.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 537 - 537
  • [27] ACCELERATED GRAFT LOSS IN KIDNEY TRANSPLANT PATIENTS WITH HIGH SCD30 LEVELS AND DSA WITH HIGH MFI - IMPLICATIONS FOR THE DEFINITION OF UNACCEPTABLE ANTIGENS
    Zecher, D.
    Preiss, A.
    Bach, C.
    Utpatel, K.
    Spriewald, B.
    Banas, B.
    Suesal, C.
    TRANSPLANT INTERNATIONAL, 2019, 32 : 13 - 13
  • [28] Long Term Outcomes of Deceased Donor (DD) Transplants in Highly-HLA Sensitized Patients (HS) Desensitized with IVIG plus Single-Dose (SD) Rituximab.
    Vo, Ashley A.
    Toyoda, Mieko
    Ge, Shili
    Lai, Chih-Hung
    Cao, Kai
    Reinsmoen, Nancy
    Peng, Alice
    Villicana, Rafael
    Jordan, Stanley C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 561 - 562
  • [29] Desensitization Protocol Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab in Highly Sensitized Kidney Transplant Recipients.
    Okada, M.
    Hiramitsu, T.
    Tomosugi, T.
    Futamura, K.
    Narumi, S.
    Goto, N.
    Watarai, Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 790 - 791
  • [30] Interim Analysis of a Double-Blinded Placebo Controlled Trial of IVIG v. IVIG plus Rituximab for Desensitization of Highly-HLA Sensitized (PRA >80%) (HS) Deceased Donor (DD) Candidates
    Vo, A.
    Choi, J.
    Lukovsky, M.
    Toyoda, M.
    Ge, S.
    Kahwaji, J.
    Peng, A.
    Villicana, R.
    Najjar, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 76 - 77
12345